Changes in the rates and characteristics of gamma hydroxybutyrate (GHB)‐related death in Australia, 2001–2023
Drug and Alcohol Review · 2025
DOI: 10.1111/dar.13940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Review, 2025. Verfasst von Shane Darke und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Sodium Oxybate, Drug Overdose, Substance-Related Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Drug and Alcohol Research Centre.
Abstract (Originalsprache)
Introduction
In recent years gamma hydroxybutyrate (GHB) use appears to have increased. This study aimed to determine: (i) population rates of GHB‐related death in Australia, 2001–2021; and (ii) whether there have been changes in the characteristics of GHB‐related death in Australia over the period 2001–2023.
Methods
Retrospective study of all Australian cases in which GHB was a mechanism contributory to death retrieved from the National Coronial Information System ( n = 217). Joinpoint regression models were used to analyse trends in overall rates.
Results
Death rates were stable between 2001 and 2015 (‘stable period’) (annual percent change [APC] = 3.7) but showed marked acceleration between 2016 and 2021 (‘accelerated period’) (APC = 44.4). Circumstances of death were: unintentional toxicity (81.6%), intentional toxicity (5.1%), self‐harm (6.0%), traumatic injury (7.4%). Compared to the stable period, later cases were slightly older (34.2 vs. 30.7 years, p < 0.05), less likely to be employed (odds ratio [OR] 0.4), but more likely to have substance use problems (OR 3.9), a history of injecting drug use (OR 3.5), mental health problems (OR 3.6), and to have present in their blood at toxicological screening opioids (OR 3.2) and hypnosedatives (OR 3.7). The median blood GHB concentration was 170 mg/L, (range 0–3210), which did not change significantly. There were no differences in major organ pathology, but the proportion with aspiration pneumonia declined (OR 0.4). Discussion and Conclusions GHB‐related death rates increased from 2016, accompanied by changes in case characteristics. In recent years GHB use appears to have extended to a population more likely to have substance use problems and use other respiratory depressants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
- Sydney Medical School, The University of Sydney, Sydney, Australia.
- Discipline of Psychiatry, UNSW Sydney, Sydney, Australia.
ORCID-Profile: Shane Darke, Amy Peacock
Förderung
- National Drug and Alcohol Research Centre
Zitieren
APA
Darke, S., Duflou, J., Chrzanowska, A., Farrell, M., Lappin, J., & Peacock, A. (2025). Changes in the rates and characteristics of gamma hydroxybutyrate (GHB)‐related death in Australia, 2001–2023. Drug and Alcohol Review. https://doi.org/10.1111/dar.13940
Vancouver
Darke S, Duflou J, Chrzanowska A, Farrell M, Lappin J, Peacock A. Changes in the rates and characteristics of gamma hydroxybutyrate (GHB)‐related death in Australia, 2001–2023. Drug and Alcohol Review. 2025. doi:10.1111/dar.13940
BibTeX
@article{Darke2025,
author = {Darke, Shane and Duflou, Johan and Chrzanowska, Agata and Farrell, Michael and Lappin, Julia and Peacock, Amy},
title = {Changes in the rates and characteristics of gamma hydroxybutyrate (GHB)‐related death in Australia, 2001–2023},
journal = {Drug and Alcohol Review},
year = {2025},
doi = {10.1111/dar.13940}
}
EUVIMED